rts logo

Moderna Inc (MRNA) Analysis & Opinions from Experts

Moderna Inc (NASDAQ: MRNA) is -60.39% lower on its value in year-to-date trading and has touched a low of $35.80 and a high of $170.47 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MRNA stock was last observed hovering at around $39.56 in the last trading session, with the day’s loss setting it -0.17%.

Currently trading at $39.39, the stock is -6.63% and -15.70% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 35.46 million and changing -0.43% at the moment leaves the stock -56.86% off its SMA200. MRNA registered -54.30% loss for a year compared to 6-month loss of -71.25%. The firm has a 50-day simple moving average (SMA 50) of $46.7268 and a 200-day simple moving average (SMA200) of $91.31068.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The stock witnessed a 6.63% gain in the last 1 month and extending the period to 3 months gives it a -38.59%, and is -5.83% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.77% over the week and 6.37% over the month.

Moderna Inc (MRNA) has around 5600 employees, a market worth around $15.09B and $5.07B in sales. Profit margin for the company is -43.84%. Distance from 52-week low is 10.03% and -76.89% from its 52-week high. The company has generated returns on investments over the last 12 months (-16.81%).

with sales reaching $1.05B over the same period.The EPS is expected to grow by 24.34% this year, but quarterly earnings will post -51.93% year-over-year. Quarterly sales are estimated to shrink -62.48% in year-over-year returns.

Moderna Inc (MRNA) Top Institutional Holders

1206.0 institutions hold shares in Moderna Inc (MRNA), with institutional investors hold 79.19% of the company’s shares. The shares outstanding are 385.00M, and float is at 343.19M with Short Float at 11.90%. Institutions hold 71.64% of the Float.

The top institutional shareholder in the company is BAILLIE GIFFORD & CO with over 43.45 million shares valued at $5.16 billion. The investor’s holdings represent 11.3741% of the MRNA Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 39.56 million shares valued at $4.7 billion to account for 10.3568 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 25.56 million shares representing 6.6917% and valued at over $3.04 billion, while FMR LLC holds 5.5396 of the shares totaling 21.16 million with a market value of $2.51 billion.

Moderna Inc (MRNA) Insider Activity

The most recent transaction is an insider sale by Klinger Shannon Thyme, the company’s Chief Legal Officer. SEC filings show that Klinger Shannon Thyme sold 529 shares of the company’s common stock on Dec 09 ’24 at a price of $44.68 per share for a total of $23637.0. Following the sale, the insider now owns 20446.0 shares.

Still, SEC filings show that on Dec 03 ’24, Klinger Shannon Thyme (Chief Legal Officer) disposed off 112 shares at an average price of $43.30 for $4849.0. The insider now directly holds 19,837 shares of Moderna Inc (MRNA).

Related Posts